Dr. Paul Berg to Retire from Gilead Sciences’ Board of Directors
November 05 2010 - 8:30AM
Business Wire
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Paul
Berg, PhD plans to retire from the company’s Board of Directors,
effective May 2011. Dr. Berg has been a member of the company’s
Board of Directors since 1998.
“On behalf of Gilead’s Board and the senior leadership team, I
thank Paul for his invaluable contributions over the last 13
years,” said John Martin, PhD, Chairman and Chief Executive
Officer, Gilead Sciences. “Paul has been a wonderful colleague and
is someone I enjoy working with tremendously. His expertise and
judgment have helped advance our efforts to deliver therapies to
patients in need, and I look forward to his continued scientific
input and guidance.”
Dr. Berg has previously served as Professor and Chairman of the
Department of Biochemistry and Director of the Beckman Center for
Molecular and Genetic Medicine at the Stanford University School of
Medicine. He is a member of the U.S. National Academy of Sciences.
In 1980, Dr. Berg was awarded the Nobel Prize for his fundamental
studies of the biochemistry of nucleic acids. He was awarded the
National Medal of Science in 1983.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Australia.
For more information on Gilead Sciences,
please visit www.gilead.com or call the Gilead Public Affairs
Department at 1-800-GILEAD-5 (1-800-445-3235).
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2024 to Aug 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2023 to Aug 2024